Search Results
Protection Screening Programme (MÁESZ) and their processing are important [ 10 ]. Under the MÁESZ, a considerable number of people have undergone tests over the last 12 years, including ophthalmological interviews and examinations [ 10 ]. We have already
References [1]. L. Esserman Y. Shieh I. Thompson 2009 Rethinking screening for breast cancer and prostate cancer JAMA 302 1685 – 1692 . [2]. A. Kovács L. Döbrőssy A. Budai I. Boncz A. Cornides 2007
Strauss, G. M., Gleason, R. E., Sugarbaker, D. J.: Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. Chest, 1995, 107 (Suppl. 6
Nicolaides, K. H.: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat. Diagn., 2011, 31 , 7–15. Nicolaides K. H. Screening for fetal aneuploidies at 11 to 13 weeks
) questionnaires is the Canadian Problem Gambling Inventory (CPGI) ( Ferris & Wynne, 2001 ). Finally, examples of brief (1–3 items) screening tools are the one-item Screen for Problem Gambling (one-item SPG) ( Thomas, Piterman, & Jackson, 2008 ), the Lie
Esserman, L., Shieh, Y., Thompson, I.: Rethinking screening for breast cancer and prostate cancer. JAMA, 2009, 302 , 1685–1692. Thompson I
Guideline of the Ministry of Health for mammographic screening and early breast cancer detection – 2008. [Az Egészségügyi Minisztérium szakmai protokollja a mammográfiás emlőszűrésről és a korai emlőrák diagnosztikájáról – 2008.] http
” or “disordered” gamers using one of the many available screening instruments that have been created over the last two decades ( King et al., 2020 ). Some commentators have criticized the evidence as “weak” ( van Rooij et al. 2018 , p. 6), and raised
Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology: Screening examinations of premature infants for retinopathy of prematurity. Pediatrics, 2001, 108 , 809. Screening examinations of premature
Abstract
Crystal structure (polymorphism) as well as crystal shape (morphology) and size have a huge practical and commercial impact on active substances all the way from research to manufacture of the final product. For an optimal development process, it is important to have an integrated approach to these issues ranging from a systematic polymorphism screening to a controlled scale-up of the crystallization process. The polymorphism program has to be tailored according to the development stage. Particularly suitable for an early development stage is a high-throughput polymorphism screening, which is the basis for a more thorough investigation if the product proceeds further in development. Such a comprehensive polymorphism investigation involves further crystallization experiments and extensive physicochemical characterization of the various forms. In this article the high-throughput polymorphism screening method that we have developed is described. Using carbamazepine as an example, the power of this high-throughput polymorphism screening system is demonstrated. Not only were all published forms found, but also new forms were identified. In the second part of the article, important considerations for crystallization optimization are discussed, again using the example of carbamazepine.
